Vascular resection during pancreaticoduodenectomy. Ryan Turley, MD Research Fellow, Duke University
|
|
|
- Ross Russell
- 8 years ago
- Views:
Transcription
1 Vascular resection during pancreaticoduodenectomy. Ryan Turley, MD Research Fellow, Duke University
2 Vascular Resection during PD Outline Review of pancreatic adenocarcinoma Role of PD in treatment of pancreatic adenocarcinoma Theory for vascular resection for locally invasive disease Summary of current literature Types of reconstruction Duke experience Conclusions
3 Pancreatic Adenocarcinoma
4 Pancreatic Adenocarcinoma Classic Presentation Jaundice, sometimes painless Dark urine Light colored stool Labs Bilirubin Ca 19-9 (Normal < 37) less specific > 100 suggest malignancy
5 Pancreatic Adenocarcinoma Imaging Head mass with PV invasion Fine-cut CT scan High quality MRI scan Other EUS ERCP
6 Role of Pancreaticoduodenectomy (PD) PD is the only chance for cure. Mortality rates ranges from 0-8%. 5 year survival after resection ranges from 7-25%. 2 Survival after surgery is worse for patients with positive margins Bachellier, et al. Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile. Am J Surgery 2001;182: Zervos EE et al. Surgical management of early-stage pancreatic cancer. Cancer Control. 2004; 11:23-31.
7 Pancreatic Adenocarcinoma SMV and Portal Venous Resection - Theory Grossly positive margins after resection associated with early recurrence. Close relationship between pancreatic head and superior mesenteric vein. Barriers to margin free resection include tumor involvement of SMV. Invasion of SMV can occur without retroperitoneal invasion. SMV not always accurately defined on pre-operative imaging.
8 Pancreatic Adenocarcinoma SMV/PV invasion Loss of the fat plane on CT Absence of normal pancreatic parenchyma between the low-density tumor and the vein wall
9 NCCN Practice Guidelines v Resectable No distant metastases Clear fat plane around celiac and superior mesenteric artery. Patent SMV/PV Borderline Resectable Severe unilateral or bilateral SMV/portal impingement Less than 180 degree tumor abutment of SMA Abutment or enasement of hepatic artery, if reconstructible. SMV occlusion, if of a short segment, and reconstructible. SMA or celiac encasement < 180 degrees. Unresectable Distant Metastases Greater than 180 degree SMA encasement, any celiac abutment. Unreconstructible SMV/Portal Vein Aortic invasion or encasement. Metastases to lymph nodes beyond the field of resection.
10 Flow Diagram- NCCN Guidelines Pancreatic Protocol CT scan Resectable Borderline Unresectable Resection Clinical Trial Neoadjuvant Therapy Resection Neoadjuvant Therapy Chemotherapy/ Radiation Restage Systemic Therapy Resection
11 History First PD with SMV reconstruction by Moore et al. at the University of Minnesota in Symbas et al. concluded autologous grafts vein grafts remained patent while synthetic prosthesis had high rates of occlusion in Asada et al. in Japan reported radical pancreatectomy with PVR in First attempts in the 1970s by Fortner produced poor results with high morbidity and mortality. Reemergence in the 1990s by the MD Anderson group.
12 Current literature Modern debate is charged in comparing vascular resection for isolated invasion of SMV, PV, or SMV-PV confluence. Reported Morbidity 25-55% PD with Vascular Resection has not yet been universally accepted due to failure to prove: (1) the procedure can be performed with acceptable morbidity and mortality even if margin free resections are increased. (2) PD with SM-PVR has survival similar characteristics as standard PD.
13 Reconstruction options V1 Tangential resection with saphenous vein patch V2 Segmental resection with splenic vein ligation and primary anastomosis V3 Segmental resection with splenic vein ligation and interposition graft. V4 Segmental resection without splenic vein ligation and primary anastomosis. V5 Segmental resection without splenic vein ligation and interposition graft.
14 Available SMV-PVR techniques Vein Patch Greater Saphenous Vein Continuous 6-0 prolene Choice for less extensive tumor involvement < 1/3 vessel circumference
15 Interposition Grafting More extensive tumor involvement (> 1/3 vessel circumference) Interrupted 6-0 prolene Splenic vein can be ligated or reimplanted in side of interposition graft.
16 Interposition Graft Graft types Splenic vein Left Renal Vein Internal Jugular Ovarian Vein Femoral Vein*
17 Primary Reconstruction A. Pancreatic head tumor and involvement of the portal vein. B. En-bloc PD with Segmental portal venous resection. C. Reconstruction of the portal vein.
18 Previous Studies Author Location N (%) Mortality 30 days (%) Sindelar 1989 Trede 1990,97 Allema 1994 Fortner Harrison 1996 Roder 1996 Morbidity (%) NCI Mannheim 60 (10.7) Median Survival Amsterdam 20 (11.4) MSK 58 (17.5) 5 12 (Re-X-Lap) Munich 31 (10.4) Neg Margins (%)
19 Previous Studies Author Location N (%) Mortality 30 days (%) Sindelar 1989 Trede 1990,97 Allema 1994 Fortner Harrison 1996 Roder 1996 Morbidity (%) NCI Mannheim 60 (10.7) Median Survival Amsterdam 20 (11.4) MSK 58 (17.5) 5 12 (Re-X-Lap) Munich 31 (10.4) Neg Margins (%)
20 Previous Studies Author Location N (%) Mort. 30 days (%) Leach Furman 1996, 98 Tseng 2004 Imaizumi 1998 Nakao 1993, 95 Takahashi 1994, 97 Klempnauer 1996 MD Anderson MD Anderson 31 (41.7) 110 (38) Tokyo 172 (69) Nagoya (Japan) 104 (78) Keio 107 (55.7) Hannover 37 (19.6) Morbidity (%) Median Survival % 5-year Neg Margins (%) (Re-X-Lap) 9.0
21 Previous Studies Author Location N (%) Mort. 30 days (%) Leach Furman 1996, 98 Tseng 2004 Imaizumi 1998 Nakao 1993, 95 Takahashi 1994, 97 Klempnauer 1996 MD Anderson MD Anderson 31 (41.7) 110 (38) Tokyo 172 (69) Nagoya (Japan) 104 (78) Keio 107 (55.7) Hannover 37 (19.6) Morbidity (%) Median Survival % 5-year Neg Margins (%) (Re-X-Lap) 9.0
22 Previous Studies Author Location N (%) Mort. 30 days (%) Leach Furman 1996, 98 Tseng 2004 Imaizumi 1998 Nakao 1993, 95 Takahashi 1994, 97 Klempnauer 1996 MD Anderson MD Anderson 31 (41.7) 110 (38) Tokyo 172 (69) Nagoya (Japan) 104 (78) Keio 107 (55.7) Hannover 37 (19.6) Morbidity (%) Median Survival % 5-year Neg Margins (%) (Re-X-Lap) 9.0
23 Duke Experience Hypothesis Superior mesenterico-portal venous tumor invasion is function of location and not a harbinger of metastatic disease or worse outcome after resection. Combined pancreaticoduodenectomy with vascular resection offers previously unresectable patients a chance for cure without significant additional morbidity or mortality.
24 Duke Experience 204 patients who underwent PD for pancreatic adenocarcinoma from Patients who underwent PD with VR (N=42) were compared to patients who underwent standard PD (N=162). Vascular reconstructions were performed by a vascular surgeon using primary repair (N=7), vein patch (N=26), or interposition grafting (N=8) with saphenous or femoral vein conduit.
25 Inclusion Criteria All patients undergoing standard PD or PD with VR from at Duke. Pathology confirming Pancreatic Ductal Adenocarcinoma.
26 Exclusion criteria Patients with significant missing clinicopathological data. All tumors not described in surgical pathology as pancreatic adenocarcinoma. Previous pancreas surgery.
27 Methods All available post-operative CT scans reviewed for patency by Duke radiology fellow KP. 2 test was used to compare categorical variables. Independent t tests were used to evaluate continuous variables. Survival and follow-up were calculated from the time of surgery to date of death or last follow-up. Overall survival was estimated using the method of Kaplan and Meier. The log-rank test was used to evaluate differences between survival curves. Multivariate analyses of the effects of potential prognostic factors on survival were done using a Cox proportional hazards regression.
28 Demographics PD + VR (n=42) Standard PD (n=162) P-value Gender, n (%) Male 22 (62) 81 (50) 0.97 ( ( 2 ) Female 16 (38) 81 (50) Med (mean) age (yr) 63.5 (62.4) 66 (64.5) 0.30 (T-test) Range Race, n (%) Caucasian 33 (79) 126 (78) 0.93 ( ( 2 ) African-American American 8 (19) 32 (20) Other 1 (1) 4 (2) Med (mean) FU 10.7 (19.20) 13.1 (17.6) 0.67 (T-test) Range ( ) 123.7) ( )
29 Clinicopathological PD + VR (n=42) Standard PD (n=162) P-value Neoadjuvant CRT, n (%) Yes 23 (55) 73 (45) 0.26 ( ( 2 ) No 19 (45) 89 (55) Path Tumor Size (cm) Median (Mean) 3 (3.4) 2.5 (2.6) (T-test) Range (1.5-7) (0-7)*
30 Clinicopathological PD + VR (n=42) Standard PD (n=162) P-value Neoadjuvant CRT, n (%) Yes 23 (55) 73 (45) 0.26 ( ( 2 ) No 19 (45) 89 (55) Path Tumor Size (cm) Median (Mean) 3 (3.4) 2.5 (2.6) (T-test) Range (1.5-7) (0-7)*
31 Comorbidities Coronary Artery Disease PD + VR (n=42) Standard PD (n=162) P-value 6 (14) 23 (14) 0.99 ( ( 2 ) Diabetes 10 (24) 41 (25) 0.84 ( ( 2 ) COPD 7 (4) 0 (0) 0.17 ( ( 2 ) Chronic Renal Insufficiency 5 (3) 1 (2) 0.81 ( ( 2 ) Hypertension 20 (48) 78 (48) 0.95 ( ( 2 ) Congestive Heart Failure 1 (2) 3 (2) 0.83 ( ( 2 )
32 Clinicopathological PD + VR (n=42) Standard PD (n=162) P-value Neg Margins, n (%) 31 (73) 117 (72) 0.84 ( ( 2 ) Positive LN, n (%) 21 (50) 61 (38) 0.14 ( ( 2 ) Histological Grade (n=181), n (%) 1 Well Diff 2 Mod Diff 3 Poor Diff 4 (10) 21 (52) 15 (38) 22 (16) 75 (53) 44 (31) 0.59 ( ( 2 )
33 Clinicopathological Length of Stay Median (mean) Estimated Blood Loss ml Median (mean) (n=162) PD + VR (n=42) Standard PD (n=162) P-value 13 (15) 12 (15) 0.99 (T-test) 875 (1040) 550 (700) (T-test) Readmission in 30 days, n (%) 15 (36) 49 (30) 0.50 ( ( 2 ) Mortality, n (%) 2 (5) 6 (4) 0.73 ( ( 2 )
34 Clinicopathological Length of Stay Median (mean) Estimated Blood Loss ml Median (mean) (n=162) PD + VR (n=42) Standard PD (n=162) P-value 13 (15) 12 (15) 0.99 (T-test) 875 (1040) 550 (700) (T-test) Readmission in 30 days, n (%) 15 (36) 49 (30) 0.50 ( ( 2 ) Mortality, n (%) 2 (5) 6 (4) 0.73 ( ( 2 )
35 Morbidity PD + VR (n=42) Standard PD (n=162) P-value (X 2 ) PJ Leak 4 (9) 30 (18) 0.16 Delay Gastric Emptying 8 (19) 22 (14) 0.37 Abscess 10 (24) 20 (12) 0.06 DVT 7 (17) 8 (5) 0.01 GI Bleed 4 (9) 7 (4) 0.19 Wound Disruption 16 (38) 63 (38) 0.93 Reoperation* 8 (19) 28 (17) 0.80 Fascial Dehiscence 0 (0) 2 (1) 0.46 ECF 3 (7) 4 (2) 0.15 *Any operation related to initial Whipple operation
36 Morbidity PD + VR (n=42) Standard PD (n=162) P-value (X 2 ) PJ Leak 4 (9) 30 (18) 0.16 Delay Gastric Emptying 8 (19) 22 (14) 0.37 Abcess 10 (24) 20 (12) 0.06 DVT 7 (17) 8 (5) 0.01 GI Bleed 4 (9) 7 (4) 0.19 Wound Disruption 16 (38) 63 (38) 0.93 Reoperation* 8 (19) 28 (17) 0.80 Fascial Dehiscence 0 (0) 2 (1) 0.46 ECF 3 (7) 4 (2) 0.15 *Any operation related to initial Whipple operation
37 Morbidity PD + VR (n=42) Standard PD (n=162) P-value (X 2 ) C. Diff Infection 3 (7) 15(10) 0.67 MI 1 (2) 4 (2) 0.97 Biliary Leak 1 (2) 4 (2) 0.96 Perc Drain 9 (22) 25 (15) 0.33 Pneumonia 3 (7) 10 (6) 0.82 Arrhythmia 6 (14) 13 (8) 0.21
38 Univariate Analysis of Survival Log Rank Test of Equality Variable P-value Vascular Resection 0.89 Sex (F vs M) 0.98 Tumor Size > 2 cm 0.03 Neoadjuvant CRT Perineural Invasion (n=192) Vascular Invasion (n=183) <0.001 Positive Margins 0.01 Positive LN Grade (High vs Moderate/Low) (n=181) 0.09
39 Overall Survival Months after Surgery Control (162)
40 Overall Survival Log-rank test for equality of survivor functions p= Months after Surgery Control (162) PVR (42)
41 Multivariate Analysis PVR (n=40) Standard PD (n=137) Hazard Ratio 95% CI P-value Vascular Resection Tumor Size (cont) Neoadjuvant CRT Positive Margins Negative LN (Cont) Positive LN (Cont) <0.01 Grade (Cont)
42 Multivariate Analysis (No Grade) PVR (n=42) Standard PD (n=156) Hazard Ratio 95% CI P-value Vascular Resection Tumor Size (cont) Neoadjuvant CRT Positive Margins Negative LN (Cont) Positive LN (Cont) <0.01
43 SMV-PV Reconstruction Outcomes Status N % Patent SMV/PV Occlusion 3 8 Narrowing or Partial Vein Occlusion 6 17
44 SMV-PV Reconstruction Outcomes Duke Kaplan-Meier Estimate Months After Reconstruction *Only patients with Post-operative operative CT analyzed. Hepatic artery reconstruction excluded.
45 Arterial Reconstructions 6 patients underwent arterial reconstruction. 5 with post-operative imaging 4 Thrombosed 1 Indeterminant
46 Patent Reconstruction 78 year old woman. Surgery 2/27/08 Technique Femoral Interposition Graft Path T3N0, Margin Negative Patent 5/12/09 Disease Free 5/18/10 Survival 26.6 months Complications: ED Visit for leg Edema and later a DVT.
47 Partial Occlusion 73 year old man. Surgery 8/26/98 Technique Primary Venorraphy. Path T2N0, Margin Negative Non-occlusive thombus 9/16/02 on surveillance CT. Recurrence 6/12/02. Death 9/17/02 Survival 48.2 months Complications: None significant
48 Early Partial Occlusion, Late Failure 52 year old woman. Surgery 3/19/08 Technique IMV Patch Path T3N0, Margin Negative Partial Occlusion - 12/1/08 Surveillance CT scan Total Occlusion - 7/13/09 Recurrence Confirmed - 5/15/09 Death 1/31/10 Survival 21.8 months Complications Wound Infection, Failure to Thrive early in post-operative course.
49 Early Failure < 6 months 66 year old woman. Surgery 10/21/08 Technique Femoral Interposition Graft Path T3N0, Margin Negative SMV Occluded 11/15/08 with collateralization. CT scan for fever workup. Recurrence 3/10/09 Hospice Care Survival 15.3 months Complications: None significant
50 Morbidity Defined as major complications including 30 day mortality, reoperation, Pancreatic leak, GI bleed, Abscess, Fluid collection, Pneumonia, and MI as previously described by Tseng et al. J Gastrointest Surg Dec;8(8):935-49
51 Mortality
52 Median Survival
53 Negative Margins
54 Conclusions Patients undergoing vascular resection had slightly larger tumors. Vascular resection was associated with greater blood loss and likelihood being diagnosed with a lower extremity DVT. Perioperative mortality, readmission rates, length of stay, and overall complication rates does significantly differ between standard PD and PD with VR. Duke outcomes are equivalent or superior to other institutions.
55 Acknowledgments Dr. White Dr. Barbas Dr. Tyler Dr. Ceppa Dr. Pappas Dr. McCann Dr. Clary
Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease
Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease Matthew HG Katz, MD, Peter WT Pisters, MD, FACS, Douglas B Evans, MD, FACS, Charlotte C Sun, DrPH, MPH, Jeffrey
Preoperative drainage is always indicated in malignant CBD strictures PRO. Horst Neuhaus Evangelisches Krankenhaus Düsseldorf, Germany
Preoperative drainage is always indicated in malignant CBD strictures PRO Horst Neuhaus Evangelisches Krankenhaus Düsseldorf, Germany Background Jaundice is associated with high perioperative morbidity
To Whipple or Not to Whipple, that is the Question: Evaluating the Resectability of Pancreatic Adenocarcinoma
August 2009 To Whipple or Not to Whipple, that is the Question: Evaluating the Resectability of Pancreatic Adenocarcinoma Christina Ramirez, Harvard Medical School Year III Gillian Lieberman, MD Agenda
PANCREATIC AND PERIAMPULLARY TUMORS: PANCREATICODUODENECTOMY. Dr. Shailesh V. Shrikhande
PANCREATIC AND PERIAMPULLARY TUMORS: PANCREATICODUODENECTOMY Dr. Shailesh V. Shrikhande Associate Professor & Consultant Surgeon GI and HPB Surgical Oncology Tata Memorial Hospital, Mumbai INDIA HELICAL
The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality. Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006
The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006 Overview Pancreatic ductal adenocarcinoma Pancreaticoduodenectomy
restricted to certain centers and certain patients, preferably in some sort of experimental trial format.
Managing Pancreatic Cancer, Part 4: Pancreatic Cancer Surgery, Complications, & the Importance of Surgical Volume Dr. Matthew Katz, Surgeon, MD Anderson Cancer Center, Houston, TX I m going to talk a little
The Whipple Procedure. Sally Hodges, Ph.D.(c) Given the length and difficulty of the procedure, regardless of the diagnosis, certain
The Whipple Procedure Sally Hodges, Ph.D.(c) Preoperative procedures Given the length and difficulty of the procedure, regardless of the diagnosis, certain assurances must occur prior to offering a patient
Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background
Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the
Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma
Ann Surg Oncol DOI 10.1245/s10434-008-0295-2 ORIGINAL ARTICLE HEPATOBILIARY AND PANCREATIC TUMORS Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma Matthew H.
Extended Radical Whipple Resection for Cancer of the Pancreatic Head: Operative Procedure and Results
How I Do It Dig Surg 1998;15:299 307 Received: February 17, 1997 Accepted: March 20, 1997 T. Imaizumi F. Hanyu N. Harada T. Hatori A. Fukuda Department of Gastroenterological Surgery, Tokyo Women s Medical
L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
Evidence tabel Lokaal palliatieve behandelingen
Auteurs, jaartal Mate van bewijs Studie type Follow-up Populatie (incl. steekproef-grootte) Patienten kenmerken Interventie Controle Resultaten Conclusie Opmerkingen, commentaar Hartgrink, 2002 The Netherlands
Cancer of the Pancreas
Cancer of the Pancreas James H. North Jr., M.D., F.A.C.S. It is estimated that in 2007, 37,170 patients will be diagnosed with cancer of the pancreas and 33,370 patients will die of this disease. 1 The
J Clin Oncol 24:2897-2902. 2006 by American Society of Clinical Oncology INTRODUCTION
VOLUME 24 NUMBER 18 JUNE 20 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Perioperative CA19-9 Levels Can Predict Stage and Survival in Patients With Resectable Pancreatic Adenocarcinoma
Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50
General Data Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50 The vast majority of the patients in this study were diagnosed
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:
Cancer of the Cardia/GE Junction: Surgical Options
Cancer of the Cardia/GE Junction: Surgical Options Michael A Smith, MD Associate Chief Thoracic Surgery Center for Thoracic Disease St Joseph s Hospital and Medical Center Phoenix, AZ Michael Smith, MD
David R. DeHaas, Jr. MD Sacred Heart Medical Center at RiverBend
David R. DeHaas, Jr. MD Sacred Heart Medical Center at RiverBend 1. To review the surgical history of the Whipple procedure for periampullary tumors. 2. To review the differential diagnosis for patients
Kimberly Kirkwood, M.D. Professor of Pancreatic and GI Surgery. Risk Factors
: What Can Surgeons Do to Maximize Survival? Kimberly Kirkwood, M.D. Professor of Pancreatic and GI Surgery UCSF Postgraduate Course, General Surgery Maui, HI March 22, 2011 In 2010: New Cases: 43,140
KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA
KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA O.E. Stakhvoskyi, E.O. Stakhovsky, Y.V. Vitruk, O.A. Voylenko, P.S. Vukalovich, V.A. Kotov, O.M. Gavriluk National Canсer Institute,
Understanding. Pancreatic Cancer
Understanding Pancreatic Cancer Understanding Pancreatic Cancer The Pancreas The pancreas is an organ that is about 6 inches long. It s located deep in your belly between your stomach and backbone. Your
Preoperative Laboratory and Diagnostic Studies
Preoperative Laboratory and Diagnostic Studies Preoperative Labratorey and Diagnostic Studies The concept of standardized testing in all presurgical patients regardless of age or medical condition is no
Oxford University Hospitals
Oxford University Hospitals NHS Trust Department of Hepatobiliary and Pancreatic Surgery About Pancreatic Surgery A guide for patients and relatives Introduction This booklet has been written to provide
Pancreaticoduodenectomy (Pylorus-Preserving Whipple Procedure)
Pancreaticoduodenectomy (Pylorus-Preserving Whipple Procedure) Operative Indications: Pancreaticoduodenectomy, or the Whipple procedure, may be indicated for a variety of benign and malignant diseases.
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
Results of Surgery in a New Lung Institute in South Texas Focused on the Treatment of Lung Cancer
Results of Surgery in a New Lung Institute in South Texas Focused on the Treatment of Lung Cancer Lung cancer accounts for 13% of all cancer diagnoses and is the leading cause of cancer death in both males
Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
Pancreatic Cancer: FDA Approved Treatments and Clinical Trials
Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Vincent J Picozzi MD MMM Virginia Mason Medical Center Seattle WA 1 Pancreatic cancer is the hardest cancer of all to treat 2 Pancreatic cancer:
Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl, Andrew Hope, Thomas K Waddell, Shaf Keshavjee,
Pancreatic Cancer. The Killer that must be discovered early. Dr Alfred Kow Wei Chieh
Pancreatic Cancer The Killer that must be discovered early 27 th June 2015 Dr Alfred Kow Wei Chieh Consultant Department of Surgery Division of HPB Surgery & Liver Transplantation & Assistant Dean (Education)
Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines
Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines April 2008 (presented at 6/12/08 cancer committee meeting) By Shelly Smits, RHIT, CCS, CTR Conclusions by Dr. Ian Thompson, MD Dr. James
How to treat early gastric cancer. Surgery
How to treat early gastric cancer Surgery Mark I. van Berge Henegouwen Department of Surgery, AMC, Amsterdam Director upper GI surgical unit Academic Medical Center Upper GI surgery at AMC 100 oesophagectomies
Translocation Renal Cell Carcinomas
Translocation Renal Cell Carcinomas Cora N. Sternberg, MD, FACP Chair, Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Kidney cancer is not a single disease Clear cell (75%)
Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.
Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Abstract This paper describes the staging, imaging, treatment, and prognosis of renal cell carcinoma. Three case studies
Clinical Indications and Results Following Chest Wall Resection
Clinical Indications and Results Following Chest Wall Resection for Recurrent Malignant Pleural Mesothelioma Ali SO, Burt BM, Groth SS, DaSilva MC, Yeap BY, Richards WG, Baldini EH and Sugarbaker DJ. Division
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
A912: Kidney, Renal cell carcinoma
A912: Kidney, Renal cell carcinoma General facts of kidney cancer Renal cell carcinoma, a form of kidney cancer that involves cancerous changes in the cells of the renal tubule, is the most common type
Stomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda
Stomach (Gastric) Cancer Prof. M K Mahajan ACDT & RC Bathinda Gastric Cancer Role of Radiation Layers of the Stomach Mucosa Submucosa Muscularis Serosa Stomach and Regional Lymph Nodes Stomach and Regional
Hepatocellular Carcinoma (HCC)
Abhishek Vadalia Introduction Chemoembolization is being used with increasing frequency in the treatment of solid hepatic tumors such as Hepatocellular Carinoma (HCC) & rare Cholangiocellular Carcinoma
Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
Open Ventral Hernia Repair
Ventral Hernias Open Ventral Hernia Repair UCSF Postgraduate Course in General Surgery Maui, HI March 21, 2011 Hobart W. Harris, MD, MPH Ventral Hernias: National Experience Occur following 11-23% of laparotomies,
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
Lenox Hill Hospital Department of Surgery General Surgery Goals and Objectives
Lenox Hill Hospital Department of Surgery General Surgery Goals and Objectives Medical Knowledge and Patient Care: Residents must demonstrate knowledge and application of the pathophysiology and epidemiology
Liver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco
Liver Transplantation for Hepatocellular Carcinoma John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco Hepatocellular Carcinoma HCC is the 5th most common
Resection, Reduction, and Revision of Aneurysmal AV Fistulas
Resection, Reduction, and Revision of Aneurysmal AV Fistulas Patrick R. Cook DO, FACS Timothy G. Canty Jr. MD Robert J. Hye MD, FACS Kaiser Permanente San Diego, CA Aneurysmal AVF Over last decade K-DOQI
Pancreatic Carcinoma Recurrence in the Remnant Pancreas after a Pancreaticoduodenectomy
CASE REPORT Pancreatic Carcinoma Recurrence in the Remnant Pancreas after a Pancreaticoduodenectomy Raffaele Dalla Valle 1, Cristina Mancini 2, Pellegrino Crafa 2, Rodolfo Passalacqua 3 1 Department of
Locally advanced and bordeline forms of pancreatic cancer
19 May 2011 Locally advanced and bordeline forms of pancreatic cancer P r Pascal Hammel Pôle des Maladies de l Appareil Digestif Hôpital Beaujon, 92110 Clichy Université Paris VII, Denis Diderot pascal.hammel@bjn.aphp.fr
ATLAS FOR THE DELINEATION OF THE POSTOPERATIVE TREATMENT OF PANCREATIC CANCER
CONSENSUS PANEL CONTOURING ATLAS FOR THE DELINEATION OF THE CLINICAL TARGET VOLUME IN THE POSTOPERATIVE TREATMENT OF PANCREATIC CANCER Collaborators Ross A. Abrams, M.D. 1, William F. Regine, M.D. 2, Karyn
Results of streamlined regional ambulance transport and subsequent treatment of acute abdominal aortic aneurysm
CHAPTER 6 Results of streamlined regional ambulance transport and subsequent treatment of acute abdominal aortic aneurysm JW Haveman, A Karliczek, ELG Verhoeven, IFJ Tielliu, R de Vos, JH Zwaveling, JJAM
Non-coronary Brachytherapy
Non-coronary Brachytherapy I. Policy University Health Alliance (UHA) will reimburse for non-coronary brachytherapy when it is determined to be medically necessary and when it meets the medical criteria
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
Targeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
Columbia University Mesothelioma Applied Research Foundation - 2009 - www.curemeso.org. Mesothelioma Center www.mesocenter.org
Columbia University Mesothelioma Center www.mesocenter.org Multimodal clinical trials, treatment (surgery, radiation, chemotherapy) Peritoneal mesothelioma program Immunotherapy translational, experimental
Abdominal Surgery Rotation Section 7- Whipple resection. 1. Surgical considerations
Abdominal Surgery Rotation Section 7- Whipple resection 1. Surgical considerations The Whipple resection consists of a pancreaticoduodenectomy followed by anastamosis of the pancreas, liver and stomach
PET/CT in Lung Cancer
PET/CT in Lung Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria GLOBOCAN 2012 #1 #3 FDG-PET/CT
Luis D. Carcorze Soto, MD PGY-3
Luis D. Carcorze Soto, MD PGY-3 Peritoneal Surface Malignancies Peritoneum Patient Selection Operative Technique HIPEC EPIC Primary: Primary Peritoneal Carcinoma Malignant Peritoneal Mesothelioma Metastatic:
Minimally Invasive Mitral Valve Surgery
Minimally Invasive Mitral Valve Surgery Stanford Health Care offers leading, superior options in cardiac surgery, including the latest techniques and research for Minimally Invasive Cardiac surgery. Advanced
Image. 3.11.3 SW Review the anatomy of the EAC and how this plays a role in the spread of tumors.
Neoplasms of the Ear and Lateral Skull Base Image 3.11.1 SW What are the three most common neoplasms of the auricle? 3.11.2 SW What are the four most common neoplasms of the external auditory canal (EAC)
Travel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation
Travel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation Yan Xing, MD, PhD, Ryaz B. Chagpar, MD, MS, Y Nancy You MD, MHSc, Yi Ju Chiang, MSPH, Barry W. Feig, MD, George
Prognostic impact of uric acid in patients with stable coronary artery disease
Prognostic impact of uric acid in patients with stable coronary artery disease Gjin Ndrepepa, Siegmund Braun, Martin Hadamitzky, Massimiliano Fusaro, Hans-Ullrich Haase, Kathrin A. Birkmeier, Albert Schomig,
The Need for Accurate Lung Cancer Staging
The Need for Accurate Lung Cancer Staging Peter Baik, DO Thoracic Surgery Cancer Treatment Centers of America Oklahoma Osteopathic Association 115th Annual Convention Financial Disclosures: None 2 Objectives
Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence
Post- survival in completely resected stage I non-small cell lung cancer with local J-J Hung, 1,2,3 W-H Hsu, 3 C-C Hsieh, 3 B-S Huang, 3 M-H Huang, 3 J-S Liu, 2 Y-C Wu 3 See Editorial, p 185 c A supplementary
Introduction. Case History
NAOSITE: Nagasaki University's Ac Title Author(s) A Case Report of Renal Cell Carcino Shimajiri, Shouhei; Shingaki, Yoshi Masaya; Tamamoto, Tooru; Toda, Taka Citation Acta Medica Nagasakiensia. 1992, 37
Imaging of Thoracic Endovascular Stent-Grafts
Imaging of Thoracic Endovascular Stent-Grafts Tariq Hameed, M.D. Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indiana Disclosures: No relevant financial
Primary Care Management of Colorectal Cancer
Primary Care Management of Colorectal Cancer Dr. Dan Renouf, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Primary Care Management of Colorectal Cancer Survivors Daniel
بسم هللا الرحمن الرحيم
بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma
9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH
9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH Differentiated thyroid cancer expresses the TSH receptor on the cell membrane and responds to TSH stimulation by increasing
A Patient s Guide to. Pancreatic Cysts. University of Michigan Comprehensive Cancer Center
A Patient s Guide to Pancreatic Cysts University of Michigan Comprehensive Cancer Center Staff of the Comprehensive Cancer Center s Multidisciplinary Pancreatic Cancer Program provided information for
Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka
Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced
Tumor-Node-Metastasis Staging of Pancreatic Adenocarcinoma Matthew H. G. Katz, Rosa Hwang, Jason B. Fleming and Douglas B. Evans
Tumor-Node-Metastasis Staging of Pancreatic Adenocarcinoma Matthew H. G. Katz, Rosa Hwang, Jason B. Fleming and Douglas B. Evans CA Cancer J Clin 2008;58;111-125; originally published online Feb 13, 2008;
Resection of Lung Cancer Invading the Mediastinum
Resection of Lung Cancer Invading the Mediastinum Philippe G. Dartevelle MARIE-LANNELONGUE HOSPITAL GUSTAVE ROUSSY INSTITUTE INSTITUTE OF THORACIC ONCOLOGY PARIS SUD UNIVERSITY Mediastinal Invasion Superior
The evolution of rectal cancer therapy. Objectives
The evolution of rectal cancer therapy Hagen Kennecke MD MHA FRCPC Western Canada Consensus Conference September 5, 2014 Objectives Identify standard therapy: stage II/III rectal cancer Update recent adjuvant
Smoking and misuse of certain pain medicines can affect the risk of developing renal cell cancer.
Renal cell cancer Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. Renal cell cancer (also called kidney cancer or renal adenocarcinoma) is a disease in which
Surgical Treatment of Various GI Tract Cancers
Surgical Treatment of Various GI Tract Cancers By James Ouellette, DO, FACS, Surgical Oncology, Hepatobiliary Surgery Surgical treatment for most gastrointestinal (GI) cancers requires multidisciplinary
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof
7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
PSA Screening for Prostate Cancer Information for Care Providers
All men should know they are having a PSA test and be informed of the implications prior to testing. This booklet was created to help primary care providers offer men information about the risks and benefits
Overview. Total Joint Replacement in the U.S. KP National Total Joint Registry EMR Tools and Outcome Assessment: A Model for Vascular Surgery?
KP National Total Joint Registry EMR Tools and Outcome Assessment: A Model for Vascular Surgery? Liz Paxton Director of Surgical Outcomes and Analysis Overview KP Total Joint Replacement Registry Background
Secondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer
Copyright E 2007 Journal of Insurance Medicine J Insur Med 2007;39:242 250 MORTALITY Secondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer David Wesley, MD; Hugh
Facing Pancreatic Surgery? Learn about minimally invasive da Vinci Surgery
Facing Pancreatic Surgery? Learn about minimally invasive da Vinci Surgery The Condition: Pancreatitis/Pancreatic Cancer The pancreas is an organ that produces enzymes and hormones to help your body digest
Optimal Management of Splenic/Portal Vein Thrombosis. David Mauchley University of Colorado
Optimal Management of Splenic/Portal Vein Thrombosis David Mauchley University of Colorado Overview Portal Vein Thrombosis (PVT) Etiology Presentation/Clinical Aspects Diagnosis Management Cirrhotic vs.
AORTOENTERIC FISTULA. Mark H. Tseng MD Brooklyn VA Hospital February 11, 2005
AORTOENTERIC FISTULA Mark H. Tseng MD Brooklyn VA Hospital February 11, 2005 AORTOENTERIC FISTULA diagnosis and management Mark H. Tseng MD Brooklyn VA Hospital February 11, 2005 AORTOENTERIC FISTULA Aortoenteric
Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care
Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Current Status and Perspectives of Radiation Therapy for Breast Cancer
Breast Cancer Current Status and Perspectives of Radiation Therapy for Breast Cancer JMAJ 45(10): 434 439, 2002 Masahiro HIRAOKA, Masaki KOKUBO, Chikako YAMAMOTO and Michihide MITSUMORI Department of Therapeutic
Carcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology
Carcinoma of the Cervix Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Treatment Treatment Microinvasive (Stage IA1): Simple (extrafascial) hysterectomy/cone
Endoscopic Resection for Barrett s Esophagus and Early Cancer 2014 Masters of Minimally Invasive Surgery
Endoscopic Resection for Barrett s Esophagus and Early Cancer 2014 Masters of Minimally Invasive Surgery Matthew Hartwig, M.D. Duke Cancer Institute Case Presentation: Patient ER 51 y/o man with schizophrenia
Quality Scorecard overall heart attack care overall heart failure overall pneumonia care overall surgical infection rate patient safety survival
Quality Scorecard s are required to report quality statistics to the s for Medicare and Medicaid Services (CMS) and the Department of Health (DOH). This information is made available at www.hospitalcompare.hhs.gov
Lung Cancer Treatment Guidelines
Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,
Kidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
Phase 1 Trial of Preoperative, Short-Course Carbon-Ion Radiotherapy for Patients With Resectable Pancreatic Cancer
Phase 1 Trial of Preoperative, Short-Course Carbon-Ion Radiotherapy for Patients With Resectable Pancreatic Cancer Makoto Shinoto, MD 1,2 ; Shigeru Yamada, MD, PhD 1 ; Shigeo Yasuda, MD, PhD 1 ; Hiroshi
Metastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy
Metastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy Sarah Hutto,, MSIV Marc Underhill, M.D. January 27, 2009 Past History 45 yo female
After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH
After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH Professor of Medicine Department of Gastroenterology Director, Viral Hepatitis Center University of California San Francisco
Effect of Risk and Prognosis Factors on Breast Cancer Survival: Study of a Large Dataset with a Long Term Follow-up
Georgia State University ScholarWorks @ Georgia State University Mathematics Theses Department of Mathematics and Statistics 7-28-2012 Effect of Risk and Prognosis Factors on Breast Cancer Survival: Study
Breast Reconstruction Options. Department of Plastic Surgery #290 Santa Clara Homestead Campus
Breast Reconstruction Options Department of Plastic Surgery #290 Santa Clara Homestead Campus Importance of Breast Reconstruction As successes in treating breast cancer have grown, more women have been
Mesothelioma. Malignant Pleural Mesothelioma
Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latency
Contegra Pulmonary Valved Conduit Humanitarian Device Exemption (HDE) H020003
Presentation to the Pediatric Advisory Committee September 16, 2015 Contegra Pulmonary Valved Conduit Humanitarian Device Exemption (HDE) H020003 George Aggrey, MD, MPH Epidemiologist Division of Epidemiology
Male. Female. Death rates from lung cancer in USA
Male Female Death rates from lung cancer in USA Smoking represents an interesting combination of an entrenched industry and a clearly drug-induced cancer Tobacco Use in the US, 1900-2000 5000 100 Per Capita
General Rules SEER Summary Stage 2000. Objectives. What is Staging? 5/8/2014
General Rules SEER Summary Stage 2000 Linda Mulvihill Public Health Advisor NCRA Annual Meeting May 2014 National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention
Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate e P rofessor Professor Radiation Oncology
Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate Professor Radiation Oncology Disclosure Information I have no financial relationships to disclose relevant to the conten of this presentation.